Cardiol Therapeutics (CRDL) Share-based Compensation (2020 - 2026)

Cardiol Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 68.11% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (down 18.29% YoY), and the FY2025 full-year result was $7.7 million, down 24.92% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.3 million, down from $2.2 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.5 million in Q3 2024, with the low at -$528319.3 in Q2 2022.
• Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 178.56% — and 2024, when it jumped 274.45%.
• Cardiol Therapeutics' Share-based Compensation stood at $698362.7 in 2022, then grew by 6.52% to $743899.4 in 2023, then jumped by 202.86% to $2.3 million in 2024, then declined by 4.07% to $2.2 million in 2025, then plunged by 37.83% to $1.3 million in 2026.
• The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.